SCIREQ and emka TECHNOLOGIES introduce the new vivoFlow - WBP (Whole Body Plethysmograph Chamber).

The vivoFlow is fully compatible with our current system and has several design features which both improve data quality and usability.

____________ 

 vivoFlow-500px

 
 

The advantages of the vivoFlow - WBP  

_____________________

 

Collect data sooner with reduced acclimation time

 The amber tinted whole body plethysmograph chamber reduces acclimation time and variability between baseline values. Mice do not typically see amber wavelengths, the tinting allows them to quickly adjust to the chamber and settle into a quiet breathing pattern. 

Improved data reproducibility

Patented concentric pneumotachograph for industry leading noise cancellation.

Simple operation

Removable bucket chamber and removable hinged lid allows fast cleaning, easy placement and removal of subjects.

Fully integrated system

Separate module encloses sensitive components preventing risk of damage while allowing easy removal of the subject chamber for cleaning.
 
Contact us for more information on our plethysmography solutions
 
 
Request more information

Applications for Whole Body Plethysmograph

_____________________________________

Plethysmography is a versatile tool for assessing ventilatory parameters in pre-clinical studies, common applications include: asthma, control or breathing, gas challenges, just to name a few.

A focus can be done on opioid-induced respiratory depression. Central nervous system respiratory depression is a well-known side-effect of the opioid drug family and respiratory depression is the primary cause of fatal opioid overdose. Opioid research studies are needed to gain a better understanding of the pathways involved in opioid-induced respiratory depression and tolerance.

vivoFlow – WBP permits a continuous and non-invasive approach to assess changes in conscious respiratory behaviour which result from drug administration. It is the ideal approach to monitor the real-time effects on ventilatory behaviour of fentanyl, oxycodone, morphine and many others.

An example is that of Hill et al., where they examined both the signalling profile of the novel µ-opioid receptor ligand PZM21, and its capacity to induce respiratory depression. Respiratory rate and tidal volume were assessed using whole body plethysmograph chamber, comparing saline control and morphine-treated subjects to those administered PZM21. The authors’ present evidence for a dose-dependent decrease in respiratory rate, without tidal volume effects, in a similar fashion to that observed for morphine.

THE BENEFITS OF THIS APPROACH ARE:
  • Easy-to-use, no surgery required
  • Tracks conscious subjects’ ability to respond to real-time changes
  • Swivel/tether system for measurement of physiological parameters (EEG). drug infusion or blood sampling
  • Integrates easily with gas challenges, through use of automated mass flow controllers
  • Measures respiratory rate (RR), estimated tidal volume (VT), minute ventilation (MV), flow rates